Astellas Pharma Ownership
| ALPMY Stock | USD 10.08 0.20 1.95% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Astellas |
Astellas Pink Sheet Ownership Analysis
The book value of the company was presently reported as 861.58. The company last dividend was issued on the 29th of September 2022. Astellas Pharma had 125:100 split on the 2nd of April 2014. Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 14522 people.The quote for Astellas Pharma is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Astellas Pharma please contact the company at 81 3 3244 3000 or go to https://www.astellas.com.Astellas Pharma Outstanding Bonds
Astellas Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Astellas Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Astellas bonds can be classified according to their maturity, which is the date when Astellas Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Assurant 7 percent Corp BondUS04621XAK46 | View | |
| ASSURANT INC 49 Corp BondUS04621XAJ72 | View | |
| ASSURANT INC 675 Corp BondUS04621XAD03 | View | |
| US04621XAM02 Corp BondUS04621XAM02 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| AIZ 265 15 JAN 32 Corp BondUS04621XAN84 | View | |
| AGO 36 15 SEP 51 Corp BondUS04621WAE03 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Astellas Pink Sheet Analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.